A phase 1b randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VK 2809 (Primary)
Indications Hypercholesterolaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Metabasis Therapeutics

Most Recent Events

16 Nov 2016 Results of effect of VK-2809 on lipoprotein-A and Apolipoprotein B presented at the 89th Annual Scientific Sessions of the American Heart Association
15 Nov 2016 According to Viking Therapeutics Media Release, results were presented in a poster presentation at the American Heart Association (AHA) Scientific Sessions 2016.
15 Nov 2016 Results published in the Viking Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight